Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RG7652

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND AND AIMS While inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is known to result in dramatic… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Review
2018
Review
2018
Objective To evaluate the potential effects of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9-mAb) on… Expand
2017
2017
Proprotein convertase subtilisin/kexin type 9 (PCSK9) downregulates low‐density lipoprotein (LDL) receptors, thereby leading to a… Expand
2015
2015
ABSTRACTRG7652 is a fully humanized monoclonal antibody targeting human PCSK9, a regulator of serum low density lipoprotein… Expand
  • figure 1
  • figure 2
  • table I
  • figure 3
  • table II
2014
2014
RG7652 is a human immunoglobulin 1 (IgG1) monoclonal antibody (mAb) targeting proprotein convertase subtilisin/kexin type 9… Expand
2014
2014
RG7652 is a human IgG1 monoclonal antibody designed to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) binding to… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Review
2013
Review
2013
Purpose: Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates hepatic LDL receptors, playing a key role in cholesterol… Expand
2013
2013
Background: RG7652 (MPSK3169A) is a fully human IgG1 monoclonal antibody (mAb) directed against proprotein convertase subtilisin… Expand
Review
2013
Review
2013
Objectives Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates hepatic LDL receptors, playing a key role in… Expand